Cargando…
A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
LESSONS LEARNED. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small cell lung cancer showed favorable efficacy. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small lung cancer showed tolerable toxicity. BACKGROUND. Although monotherapy w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459255/ https://www.ncbi.nlm.nih.gov/pubmed/30578309 http://dx.doi.org/10.1634/theoncologist.2018-0858 |
_version_ | 1783410157285277696 |
---|---|
author | Yoshimura, Akihiro Chihara, Yusuke Date, Koji Tamiya, Nobuyo Takemura, Yoshizumi Imabayashi, Tatsuya Kaneko, Yoshiko Yamada, Tadaaki Ueda, Mikio Arimoto, Taichiro Uchino, Junji Iwasaki, Yoshinobu Takayama, Koichi |
author_facet | Yoshimura, Akihiro Chihara, Yusuke Date, Koji Tamiya, Nobuyo Takemura, Yoshizumi Imabayashi, Tatsuya Kaneko, Yoshiko Yamada, Tadaaki Ueda, Mikio Arimoto, Taichiro Uchino, Junji Iwasaki, Yoshinobu Takayama, Koichi |
author_sort | Yoshimura, Akihiro |
collection | PubMed |
description | LESSONS LEARNED. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small cell lung cancer showed favorable efficacy. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small lung cancer showed tolerable toxicity. BACKGROUND. Although monotherapy with cytotoxic agents including docetaxel or vinorelbine are recommended for elderly patients with advanced non‐small cell lung cancer (NSCLC), the outcome is not satisfactory. We evaluated the efficacy and safety of S‐1 and paclitaxel (PTX) as a first‐line cotreatment in elderly patients with advanced NSCLC. METHODS. Oral S‐1 was administered on days 1–14 every 3 weeks at 80, 100, and 120 mg per day for patients with body surface area < 1.25 m(2), 1.25–1.5 m(2), and > 1.5 m(2), respectively. PTX was administered at 80 mg/m(2) on days 1 and 8. The primary endpoint was response rate, and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. RESULTS. Seventeen patients were enrolled with response and disease control rates of 47.1% and 88.2%, respectively. Median PFS and OS were 5.6 and 35.0 months, respectively. Hematological grade 3 or 4 toxicities included leukopenia (55.8%), neutropenia (52.9%), febrile neutropenia (11.8%), and anemia (11.8%). Nonhematological grade 3 toxicities included stomatitis (23.5%), diarrhea (5.9%), and interstitial lung disease (5.9%), and grade 5 toxicities included interstitial lung disease (5.9%). CONCLUSION. This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC. |
format | Online Article Text |
id | pubmed-6459255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64592552019-06-20 A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer Yoshimura, Akihiro Chihara, Yusuke Date, Koji Tamiya, Nobuyo Takemura, Yoshizumi Imabayashi, Tatsuya Kaneko, Yoshiko Yamada, Tadaaki Ueda, Mikio Arimoto, Taichiro Uchino, Junji Iwasaki, Yoshinobu Takayama, Koichi Oncologist Clinical Trial Results LESSONS LEARNED. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small cell lung cancer showed favorable efficacy. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small lung cancer showed tolerable toxicity. BACKGROUND. Although monotherapy with cytotoxic agents including docetaxel or vinorelbine are recommended for elderly patients with advanced non‐small cell lung cancer (NSCLC), the outcome is not satisfactory. We evaluated the efficacy and safety of S‐1 and paclitaxel (PTX) as a first‐line cotreatment in elderly patients with advanced NSCLC. METHODS. Oral S‐1 was administered on days 1–14 every 3 weeks at 80, 100, and 120 mg per day for patients with body surface area < 1.25 m(2), 1.25–1.5 m(2), and > 1.5 m(2), respectively. PTX was administered at 80 mg/m(2) on days 1 and 8. The primary endpoint was response rate, and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. RESULTS. Seventeen patients were enrolled with response and disease control rates of 47.1% and 88.2%, respectively. Median PFS and OS were 5.6 and 35.0 months, respectively. Hematological grade 3 or 4 toxicities included leukopenia (55.8%), neutropenia (52.9%), febrile neutropenia (11.8%), and anemia (11.8%). Nonhematological grade 3 toxicities included stomatitis (23.5%), diarrhea (5.9%), and interstitial lung disease (5.9%), and grade 5 toxicities included interstitial lung disease (5.9%). CONCLUSION. This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC. John Wiley & Sons, Inc. 2018-12-21 2019-04 /pmc/articles/PMC6459255/ /pubmed/30578309 http://dx.doi.org/10.1634/theoncologist.2018-0858 Text en © AlphaMed Press; the data published online to support this summary are the property of the authors |
spellingShingle | Clinical Trial Results Yoshimura, Akihiro Chihara, Yusuke Date, Koji Tamiya, Nobuyo Takemura, Yoshizumi Imabayashi, Tatsuya Kaneko, Yoshiko Yamada, Tadaaki Ueda, Mikio Arimoto, Taichiro Uchino, Junji Iwasaki, Yoshinobu Takayama, Koichi A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer |
title | A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer |
title_full | A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer |
title_fullStr | A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer |
title_full_unstemmed | A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer |
title_short | A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer |
title_sort | phase ii study of s‐1 and paclitaxel combination therapy as a first‐line treatment in elderly patients with advanced non‐small cell lung cancer |
topic | Clinical Trial Results |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459255/ https://www.ncbi.nlm.nih.gov/pubmed/30578309 http://dx.doi.org/10.1634/theoncologist.2018-0858 |
work_keys_str_mv | AT yoshimuraakihiro aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT chiharayusuke aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT datekoji aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT tamiyanobuyo aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT takemurayoshizumi aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT imabayashitatsuya aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT kanekoyoshiko aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT yamadatadaaki aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT uedamikio aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT arimototaichiro aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT uchinojunji aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT iwasakiyoshinobu aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT takayamakoichi aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT yoshimuraakihiro phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT chiharayusuke phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT datekoji phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT tamiyanobuyo phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT takemurayoshizumi phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT imabayashitatsuya phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT kanekoyoshiko phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT yamadatadaaki phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT uedamikio phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT arimototaichiro phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT uchinojunji phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT iwasakiyoshinobu phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer AT takayamakoichi phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer |